The earnings call highlighted strong year-to-date revenue growth and advancement in clinical trials, alongside a positive Q3 net income and solid cash position. However, there were challenges, including a slight decrease in Q3 revenue, increased R&D expenses, and regulatory uncertainty regarding Elfabrio's dosing regimen in Europe.

Company Guidance

During the Protalix BioTherapeutics, Inc. third-quarter 2025 financial results call, the company reported total revenues of $46.436 million for the first nine months of 2025, marking a 24% increase from the previous year. Third-quarter revenues were $17.9 million, a slight 1% decrease from 2024. Sales comprised $18.6 million from Elfabrio to Chiesi, $15.4 million from Elelyso to Pfizer, and $9.1 million from Elelyso in Brazil. The company highlighted ongoing regulatory efforts with Chiesi to reexamine the CHMP's negative opinion on Elfabrio's four-week dosing regimen, while maintaining confidence in its approved two-week regimen. Protalix is advancing its PRX-115 candidate for uncontrolled gout, with a phase two trial set to initiate soon. Financially, the company has a net income of $2.4 million for the quarter, with $29.4 million in cash reserves, supporting operations for at least twelve months. Research and development expenses rose by 58% to $13.9 million, driven by pipeline investments. Gilad Mamluk, the new CFO, underscored financial discipline and revenue predictability, despite inventory fluctuations impacting quarterly sales.

Strong Year-to-Date Revenue Growth

For the first nine months of 2025, total revenues were $46.436 million, representing a 24% increase compared to the same period last year.

Advancement of PRX-115 Clinical Trial

Preparation for the phase two clinical trial of PRX-115 is well underway, with the IND filed in October and plans to initiate the trial later this year.

Positive Net Income for Q3 2025

For the three months ended September 30, 2025, net income was approximately $2.4 million or 3¢ per share, basic and diluted.

Strong Cash Position

As of September 30, 2025, the company had $29.4 million in cash and cash equivalents and short-term bank deposits, sufficient for at least twelve months.

Protalix (PLX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

PLX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Mar 12, 2026	2025 (Q4)	0.04 / -	0.1	―	―	―
Nov 13, 2025	2025 (Q3)	0.06 / 0.03	0.03	0.00% (0.00)	―
Aug 14, 2025	2025 (Q2)	0.04 / 0.00	-0.03	―	―
May 09, 2025	2025 (Q1)	0.08 / -0.05	-0.06	16.67% (<+0.01)	―
Mar 17, 2025	2024 (Q4)	0.07 / 0.10	-0.03	433.33% (+0.13)	―
Nov 14, 2024	2024 (Q3)	0.06 / 0.03	-0.04	175.00% (+0.07)	―
Aug 14, 2024	2024 (Q2)	0.02 / -0.03	0.21	-114.29% (-0.24)	―
May 10, 2024	2024 (Q1)	- / -0.06	-0.05	-20.00% (>-0.01)	―
Mar 14, 2024	2023 (Q4)	-0.03 / -0.03	-0.08	62.50% (+0.05)	―
Nov 06, 2023	2023 (Q3)	-0.07 / -0.04	-0.07	42.86% (+0.03)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

PLX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 13, 2025	$2.14	$1.93	-9.81%
Aug 14, 2025	$1.61	$1.52	-5.59%
May 09, 2025	$2.89	$1.72	-40.48%
Mar 17, 2025	$2.24	$2.45	+9.37%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Protalix Biotherapeutics (PLX) report earnings?

Protalix Biotherapeutics (PLX) is schdueled to report earning on Mar 12, 2026, TBA (Confirmed).

What is Protalix Biotherapeutics (PLX) earnings time?

Protalix Biotherapeutics (PLX) earnings time is at Mar 12, 2026, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is PLX EPS forecast?

PLX EPS forecast for the fiscal quarter 2025 (Q4) is 0.04.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing